Tomografía por emisión de positrones/tomografía computarizada: artefactos y pitfalls en pacientes con cáncer

Hopper, 2000, Body CT and oncologic imaging, Radiology, 215, 27, 10.1148/radiology.215.1.r00ap1727 Wahl, 1994, Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation, Radiology, 191, 371, 10.1148/radiology.191.2.8153308 Strauss, 1996, Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients, Eur J Nucl Med, 23, 1409, 10.1007/BF01367602 Hany, 2002, PET diagnostic accuracy: improvement with in-line PET/CT system:initial results, Radiology, 225, 575, 10.1148/radiol.2252011568 Charron, 2000, Image analysis in patients with cancer studied with a combined PET and CT scanner, Clin Nucl Med, 25, 905, 10.1097/00003072-200011000-00010 Israel, 2002, Combined functional and structural evaluation of cancer patients with a hybrid camera-based PET/CT system using 18F- FDG, J Nucl Med, 43, 1129 Costa, 2003, Positron emission and computed X-ray tomography: a coming together, Nucl Med Commun, 24, 351, 10.1097/00006231-200304000-00003 Cook, 2004, Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging, Semin Nucl Med, 34, 122, 10.1053/j.semnuclmed.2003.12.003 Beyer, 2004, Acquisition protocol considerations for combined PET/CT imaging, J Nucl Med, 45, 25S Fischman, 2003, Who should read and interpret 18F-FDG PET studies?, J Nucl Med, 44, 1197 Antoch, 2004, PET/CT or CT/PET? A radiologist’s perspective, Electromedica, 71, 64 Vogel, 2004, PET/CT: panacea, redundancy, or something in between?, J Nucl Med, 45, 15S Antoch, 2002, Whole-body positron emission tomography-CT: optimized CT using oral and iv contrast materials, Am J Roentgenol, 179, 1555, 10.2214/ajr.179.6.1791555 Dizendorf, 2003, Cause and magnitude of the error induced oral CT contrast agent in CT-based attenuation correction of PET emission studies, J Nucl Med, 44, 732 Antoch, 2004, To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT, J Nucl Med, 45, 56S Goerres, 2003, PET/CT of the abdomen: optimizing the patient breathing pattern, Eur Radiol, 13, 734, 10.1007/s00330-002-1548-2 Gordon, 1997, Whole-body positron emission tomography: normal variations, pitfalls, and technical considerations, Am J Roentgenol, 169, 1675, 10.2214/ajr.169.6.9393189 Engle, 1996, Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulations, J Nucl Med, 37, 441 Shreve, 1999, Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants, Radiographics, 19, 61, 10.1148/radiographics.19.1.g99ja0761 Tatlidil, 2002, Incidental colonic fluorodeoxyglucose uptake: correlation with colonoscopic and histopathologic findings, Radiology, 224, 783, 10.1148/radiol.2243011214 Dizendorf, 2002, Application of oral contrast media in coregistered positron emission tomography-CT, Am J Roentgenol, 179, 477, 10.2214/ajr.179.2.1790477 Vesselle, 1998, FDG PET of the retroperitoneum: normal anatomy, variants, pathologic conditions, and strategies to avoid diagnostic pitfalls, Radiographics, 18, 805, 10.1148/radiographics.18.4.9672967 Fenchel, 2002, Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings, Radiology, 223, 780, 10.1148/radiol.2233001850 Chander, 2002, Physiologic uterine uptake of FDG during menstruation demonstrated with serial combined positron emission tomography and computed tomography, Clin Nucl Med, 27, 22, 10.1097/00003072-200201000-00005 Kosuda, 1997, Uptake of 2-deoxy-2-[18F]fluoro-Dglucose in the normal testis: retrospective PET study and animal experiment, Ann Nucl Med, 11, 195, 10.1007/BF03164763 Larson, 2002, Positron emission tomography in thyroid cancer management, Semin Roentgenol, 37, 169, 10.1016/S0037-198X(02)80035-9 Nakamoto, 2005, Normal FDG distribution patterns in the head and neck: PET/CT evaluation, Radiology, 234, 879, 10.1148/radiol.2343030301 Cohade, 2003, Uptake in supraclavicular area fat (“USA fat”): description on 18F-FDG PET/CT, J Nucl Med, 44, 170 Sugawara, 1998, Pre-clinical and clinical studies of bone marrow uptake of fluorine-18-fluorodeoxyglucose with or without granulocyte colonystimulating factor during chemotherapy, J Clin Oncol, 16, 173, 10.1200/JCO.1998.16.1.173 Meyer, 1994, Increased F-18 FDG accumulation in an acute fracture, Clin Nucl Med, 19, 13, 10.1097/00003072-199401000-00004 Shon, 2003, F-18 FDG positron emission tomography and benign fractures, Clin Nucl Med, 28, 171, 10.1097/01.RLU.0000053508.98025.01 Nakamoto, 2003, Prevalence and patterns of bone metastases detected with positron emission tomography using F-18, Clin Nucl Med, 28, 302, 10.1097/01.RLU.0000057556.54046.7A Cook, 1997, Fluorine-18-FDG PET in Paget’s disease of bone, J Nucl Med, 38, 1495 Dehdashti, 1996, Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F-18]fluoro-deoxy-D-glucose, Radiology, 200, 243, 10.1148/radiology.200.1.8657920 Kalicke, 2000, Fluorine-18 fluorodeoxyglucose PET in infectious bone diseases: results of histologically confirmed cases, Eur J Nucl Med, 27, 524, 10.1007/s002590050538 Greven, 2001, Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer, Head Neck, 23, 942, 10.1002/hed.1136 Bakheet, 2000, F-18 fluorodeoxyglucose chest uptake in lung inflammation and infection, Clin Nucl Med, 25, 273, 10.1097/00003072-200004000-00007 Kapucu, 1998, Fluorine-18-fluorodeoxyglucose uptake in pneumonia, J Nucl Med, 39, 1267 Boiselle, 1998, Imaging of mediastinal lymph nodes: CT, MR, and FDG PET, Radiographics, 18, 1061, 10.1148/radiographics.18.5.9747607 Alavi, 2002, Positron emission tomography in nonmalignant thoracic disorders, Semin Nucl Med, 32, 293, 10.1053/snuc.2002.127291 Alibazoglu, 1998, Injection artifact on FDG PET imaging, Clin Nucl Med, 23, 264, 10.1097/00003072-199804000-00026 Kao, 2003, FDG uptake in a huge uterine myoma, Clin Nucl Med, 28, 249, 10.1097/01.RLU.0000053542.26097.DB Horiuchi, 1998, Four cases of Warthin’s tumor of the parotid gland detected with FDG PET, Ann Nucl Med, 12, 47, 10.1007/BF03165416 Yasuda, 2001, 18F-FDG PET detection of colonic adenomas, J Nucl Med, 42, 989 Dobert, 2002, Enchondroma: a benign osseous lesion with high F-18 FDG uptake, Clin Nucl Med, 27, 695, 10.1097/00003072-200210000-00001 Barrington, 2003, Limitations of PET for imaging lymphoma, Eur J Nucl Med, 30, 117S, 10.1007/s00259-003-1169-2 Adams, 1998, Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours, Eur J Nucl Med, 25, 79, 10.1007/s002590050197 Larcos, 1996, FDG-PET screening for cerebral metastases in patients with suspected malignancy, Nucl Med Commun, 17, 197, 10.1097/00006231-199603000-00004 Berger, 2000, FDG PET evaluation of mucinous neoplasms. Correlation of FDG uptake with histopathologic features, Am J Roentgenol, 174, 1005, 10.2214/ajr.174.4.1741005 Osman, 2003, Clinically significant inaccurate localization of lesions with PET/CT: frequency in 300 patients, J Nucl Med, 44, 240 Antoch, 2002, Focal Tracer Uptake: a potential artefact in contrast-enhanced dual-modality PET/CT scans, J Nucl Med, 43, 1339 Nakamoto, 2003, Effects of nonionic intravenous contrast agents at PET/CT imaging: phantom and canine studies, Radiology, 227, 817, 10.1148/radiol.2273020299 Kamel, 2003, Impact of metallic dental implants on CT-based attenuation correction in a combined PET/CT scanner, Eur Radiol, 13, 724, 10.1007/s00330-002-1564-2 Goerres, 2003, Artefacts at PET and PET/CT caused by metallic hip prosthetic material, Radiology, 226, 577, 10.1148/radiol.2262012141